Most GLP-1 Users Say They No Longer Recognize Themselves In The Mirror, For Better Or Worse

Survey: Weight Loss Drug Users Got Little Warning About How Their Faces Might Change

Dropping a lot of weight is supposed to end with a satisfying glance in the mirror. For many people who took GLP-1 medications, the class of drugs that includes Ozempic and Wegovy, the face looking back belonged to someone they didn’t quite know. In a new survey of beauty-conscious American adults, 72% of GLP-1 users said they no longer recognized themselves in the mirror after taking the medication, for better or worse.

Regret, oddly enough, was not the typical reaction. About two-thirds of those same users (68%) said that, knowing what they know now, they would still choose to take the drug if they could go back in time. For most of them, looking unfamiliar and wishing they had never started were two separate matters.

Many also said nobody warned them about some of the most visible changes, and plenty went looking for ways to get their old look back. One caveat belongs up front: the poll was commissioned by Revance Therapeutics, a company that sells cosmetic injectables, together with the Teoxane RHA Collection, a line of dermal fillers listed in Revance’s aesthetics portfolio. A survey that zeroes in on faces and appearance comes from sponsors with a business interest in those exact topics.

Inside the survey of GLP-1 users and beauty regulars

Talker Research ran the online survey from July 15 to July 24, 2026, polling 2,000 Americans between the ages of 26 and 60. Every person in the sample was “beauty-conscious,” which the pollsters defined as someone who gets at least one beauty treatment a year. That covers everything from facials and laser sessions to wrinkle-relaxing toxin shots, fillers, thread lifts, and plastic surgery.

Researchers set minimums for two groups inside that sample: at least 500 people who had used or were using a GLP-1, and at least 500 who had gotten an injectable treatment or would consider one. According to the release, 1,402 respondents had used or currently use a GLP-1, so people with firsthand experience of the drugs make up a large share of the poll. Talker posted its full methodology through AAPOR’s Transparency Initiative, a disclosure program run by the American Association for Public Opinion Research.

Asked why they started the medication, GLP-1 users gave reasons that went beyond the scale. Losing weight topped the list at 32%, but feeling more confident and comfortable in their bodies came in at 31%, and improving their mental and emotional well-being landed at 30%. With those three answers nearly tied, many users appear to have wanted the drugs to change how they felt about themselves as much as how much they weighed.

Because this is a poll, it records what people said about their own lives. It cannot show that the drugs caused anyone’s sense of self to shift, and a group made up of people who get beauty work done every year does not represent the country as a whole.

Weight change tops marriage and aging as an identity shaker

Across the full sample, 56% said they had gone through a “loss of identity” at some point in their lives. When asked what set it off, weight changes in either direction led the list at 39%. Major life events, such as getting married or divorced, followed at 37%, and changes that come with aging came in at 31%. Among these respondents, a shifting body shook their sense of self about as often as a wedding or a breakup did.

Those shifts rarely passed quickly. People who had lost their sense of self said the experience lasted six years on average, and they described it as mostly about the outside, rating the change as 75% external and 25% internal. One respondent summed up the feeling this way: “I just feel lost and unsure of all the things I used to be confident about.”

For many, the change is not over. Half of those who went through a major identity shift said it is still underway. That share climbed to 61% among people currently taking a GLP-1, compared with 39% among people who have never used one. A survey snapshot can’t say why the gap exists, but one reasonable guess is that people still on the drug are still watching their bodies change week to week.

GLP-1 users say major side effects went unmentioned

For anyone weighing these drugs, the education gap may be the most practical finding. Even the topics GLP-1 users heard about most often reached only about a quarter of them: mood, social, or relationship effects (24%), regaining weight after stopping the medication (23%), and changes in their relationship with food or their enjoyment of eating (22%).

Other side effects barely came up at all. Eighty percent of GLP-1 users said they received no education about losing muscle mass, which can happen when the body sheds a large amount of weight and some of it comes from muscle rather than fat. Another 81% said they were never told about facial volume loss, a hollowed look that can appear when the face loses fat along with the rest of the body. An identical 81% said they got no information about stomach and digestive side effects.

Jessie Vallejo, marketing director at Revance, argued that better preparation would help patients. “The more informed people are going in, the better equipped they are to make choices that help them feel like themselves throughout the process,” she said. Readers should weigh that message alongside the fact that her company sells treatments aimed at some of the same facial changes the survey focuses on.

Rebuilding a sense of self after GLP-1 weight loss

When their reflection changed, many GLP-1 users turned to cosmetic help. Two-thirds (66%) said they got beauty or aesthetic treatments or procedures after using the drug so they could look like themselves again.

Among everyone in the survey who had gone through an identity loss, cosmetic work actually ranked last among the ways people tried to bounce back. Getting healthier overall and spending more time with loved ones tied at the top (33% each), followed by trying new hobbies (30%), consulting medical professionals (28%), and trying aesthetic treatments and procedures (25%). Even in a sample built around people who get regular beauty treatments, everyday fixes like friends, family, and new interests came first.

Vallejo framed wider use of the drugs as a positive overall. “Expanded access to GLP-1s is a meaningful development for people’s health and well-being,” she said, adding that the data point to room for better conversations between patients and providers about the physical changes that can follow major weight loss.

A medication that changes the number on the scale can also change the face in the mirror, and patients should hear that before the first dose. That warning would land with more authority coming from a doctor than from a survey paid for by sponsors that sell treatments for the problem, but the questions it raises deserve straight answers in the exam room.

---